Zenas BioPharma, Inc.
ZBIO
$34.50
-$2.57-6.93%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 10.00M | 5.00M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 10.00M | 5.00M | -- |
| Cost of Revenue | 34.40M | 43.03M | 34.92M | 49.16M | 33.53M |
| Gross Profit | -34.40M | -43.03M | -24.92M | -44.16M | -33.53M |
| SG&A Expenses | 13.18M | 12.14M | 12.42M | 11.47M | 7.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.58M | 55.16M | 47.33M | 60.62M | 40.98M |
| Operating Income | -47.58M | -55.16M | -37.33M | -55.62M | -40.98M |
| Income Before Tax | -51.50M | -52.20M | -33.78M | -52.18M | -38.61M |
| Income Tax Expenses | -- | 20.00K | -205.00K | 429.00K | -- |
| Earnings from Continuing Operations | -51.50M | -52.22M | -33.57M | -52.60M | -38.61M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.50M | -52.22M | -33.57M | -52.60M | -38.61M |
| EBIT | -47.58M | -55.16M | -37.33M | -55.62M | -40.98M |
| EBITDA | -47.57M | -55.15M | -37.31M | -55.59M | -40.95M |
| EPS Basic | -1.22 | -1.25 | -0.80 | -1.25 | -5.02 |
| Normalized Basic EPS | -0.69 | -0.78 | -0.51 | -0.78 | -3.13 |
| EPS Diluted | -1.22 | -1.25 | -0.80 | -1.25 | -5.02 |
| Normalized Diluted EPS | -0.69 | -0.78 | -0.51 | -0.78 | -3.13 |
| Average Basic Shares Outstanding | 42.16M | 41.87M | 41.80M | 41.93M | 7.70M |
| Average Diluted Shares Outstanding | 42.16M | 41.87M | 41.80M | 41.93M | 7.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |